Atopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis. Although regulatory T cells (Tregs) have previously been studied in AD, their role remains controversial, likely owing to patient heterogeneity. Thus, we recruited adult AD patients and age-matched healthy controls, and assessed their filaggrin (FLG) genotype, serum IgE level, and eczema area and severity index (EASI). 
disease course and clinical pattern. However, there is a consensus that AD involves a Th2-predominant immune response in the acute phase followed by a Th1-predominant immune response in the chronic phase. Th17, Th22 and Th9 immune responses have been identified in AD as well. [6] [7] [8] [9] [10] Regulatory lipopolysaccharide-induced inflammation. 11 Moreover, ex vivo restimulation of mouse Tregs in the presence of IL-4 was found to upregulate the GATA3 gene, which encodes a key transcription factor of the Th2 immune response, whereas the presence of IFN-γ triggered T-bet, a transcription factor responsible for expansion of Th1 cells. 12 In mice, Bcl6 −/− Tregs are capable of suppressing colitis, but not allergic airway inflammation, and can even exacerbate the Th2 immune deviation by producing IL-4, IL-13 and IL-5 via up-regulation of GATA3. 13 In contrast, in a mouse model of helminth-driven inflammation, excess IL-4 led to expansion of Th2-like Tregs with preserved suppressive capacities. 14 Thus, recent literature proves there can be expansion of Tregs producing Th1, Th2 or Th17 cytokines in both the steady-state and under inflammatory conditions. However, whether these Tregs are still able to dampen ongoing inflammation remains controversial and could depend on the type of inflammation and the microenvironment.
In AD, the percentages of circulating Tregs are consistently found to be increased, [15] [16] [17] and this could have both favourable and unfavourable effects. Thymus-derived Tregs are increased in a mouse model of AD, 18 similar to other inflammatory disorders. 11 Interestingly, these cells can redifferentiate into Th-like cells under inflammatory conditions. 19 Moreover, restimulation of CCR6 -Tregs from AD patients with staphylococcal enterotoxin B enhances their production of IL-5 and dampens that of IL-10. 20 Similarly, restimulation of these cells with CD3 and irradiated monocytes stimulates their production of IL-5 and IL-13. 15 Thus, CCR6 -Tregs can be considered as Th2-like Tregs, as confirmed by previous work, 21 and promote AD. 15 Thus, in AD, immunosuppressive Tregs might cohabit with redifferentiated Tregs able to produce pro-inflammatory mediators. Therefore, it is not surprising that the role of Tregs in AD remains controversial. Moreover, the broad heterogeneity of AD patients and the inclusion of patients under various therapies in some studies further complicate the results. 22 The discovery that Tregs have a role in cancer has aided in the development of therapeutic antibodies to anti-cytotoxic T lymphocyte associated antigen 4 (CTLA4) and anti-programmed cell death protein 1 (PD1) as a novel and promising immunotherapeutic approach. 23 If the role of Tregs can be elucidated in AD, then the use of such therapies targeting Treg function might provide a valuable and complementary approach to AD treatment. Ideally, it would be best to uncover the role(s) of Tregs in all AD patient subpopulations. Towards that goal, we recruited adult patients not currently undergoing therapy with similar disease stages (EASI = 3.5 ± 1.0, n = 13) and known serum IgE levels, and whom we genotyped for FLG null mutations. We found that FLG null mutations target specific aspects of Tregs in AD. 26 Proportions of cells with unmethylated FoxP3i1 were calculated as previously described. 
| MATERIALS AND METHODS

| Human subjects
| Statistical analysis
Statistical analyses were performed with GraphPad Prism 6 software (GraphPad Software, La Jolla, CA). Data are presented as mean ± SEM. Statistical significance was determined between groups using a Student′s t test or one-way ANOVA followed by a Tukey post-hoc test with *P < 0.05, **P < 0.01, ***P < 0.0001.
| RESULTS
| Disease severity but not FLG null mutations correlates with expansion of circulating Tregs in AD
The literature on Tregs in AD is controversial because of patient heterogeneity in many studies. Thus, to circumvent this confounder, we recruited adult AD patients and healthy controls close in age (35.3 ± 2.6 years old, n = 23, Table S1 ). All patients and healthy controls were examined for FLG loss-of-function mutations, serum IgE level, and eczema area and severity index (EASI) ( Table S1 ). Other participant characteristics are summarized in Tables S1 and S2 . In our cohort, EASI score and serum IgE level were similar among AD patients, regardless of FLG genotype (Table S1 ). In this cohort, FLG mutated AD patients did not exhibit a more severe disease phenotype than FLG wild-type AD patients, in accordance with some studies but in contrast to others. 27, 28 We first assessed the proportion of Tregs in the total lymphocyte population, because lymphocyte population size is more stable than CD4 + T cell population size (Table S2 , Figure 1A ). Indeed, the percentage of CD4 + T cells was higher in the blood of AD patients when compared to healthy controls, regardless of FLG mutation status, serum IgE level and EASI score ( Figure 1A ). In contrast, the size of the lymphocyte population remained similar in AD patients and healthy controls (Table S2 and 
| FLG null mutations limit the expansion of circulating effector and memory Tregs in AD
We next characterized the population of circulating Tregs in the blood of AD patients and healthy control subjects. We used CCR4
and CD45RA expression to measure the levels of circulating effector
Tregs, as depicted in Figure S2 . 29 We also designated memory Tregs as CD4 Figure S3 . 30 We found that the pro- 
| FLG null mutations are associated with expansion of thymus-emigrated Tregs in AD
Recently, we showed that thymus-derived Tregs are augmented in a mouse model of AD, induced by topical application of vitamin D3. 18 Here, we assessed if this also holds true for patients with AD. We gated thymus-derived Tregs as depicted in Figure S3 . 30 We found the proportion of thymus-derived Tregs to be signifi- Figure S1 , effector (CD45RA -CCR4 + ) Tregs as depicted in Figure S2 , and memory (CD45RA -ICOS +/-CD31 +/-) Tregs as depicted in Figure S3 .
Results show cell frequencies in the lymphocyte population as calculated in Materials and Methods. Percentages of (A) CD4 + cells, (B) Tregs, (C) effector Tregs and (D) memory Tregs. Data were analysed using a Student′s t test or one-way ANOVA followed by a Tukey post-hoc test with *P < 0.05, **P < 0.01, ***P < 0.0001. Healthy controls are designated as CTRL (n = 8); AD patients as AD (n = 11), including patients without a FLG null mutation as AD WT/WT (n = 5) and patients with a FLG null mutation as AD FLG MUT (n = 6). AD patients were also stratified according to serum IgE level (<100 kUI/l, n = 4; >100 kUI/l, n = 7) or EASI score (<5, n = 7; >5, n = 4) thymus-emigrated (CD4
as depicted in Figure S3 . 30 Enhanced expansion of mature naïve 
| Proportions of cells with demethylated
FOXP3i1 are not altered in the blood of patients with AD
The literature is contradictory on the immunosuppressive capacity of Tregs in AD. One study concluded that the autoimmune reaction in severe AD is due to an attenuated Treg suppressive function, 34 whereas another study found no difference in Treg immunosuppressive capacity in AD patients and healthy donors. 15 Moreover, bulk Figure S3 . Results show cell frequencies in the lymphocyte population as calculated in Materials and Methods. Percentages of (A) thymus-derived, (B) mature naïve and (C) recently thymus-emigrated Tregs. Data were analysed using a Student′s t test or one-way ANOVA followed by a Tukey post-hoc test with *P < 0.05, **P < 0.01. Healthy controls are designated as CTRL (n = 8); AD patients as AD (n = 11), including patients without a FLG null mutation as AD WT/WT (n = 5) and patients with a FLG null mutation as AD FLG MUT (n = 6). AD patients were also stratified according to serum IgE level (<100 kU/l, n = 4; >100 kU/l, n = 7) or EASI score (<5, n = 7; >5, n = 4) 35 We found no difference in the proportion of Tregs with demethylated FOXP3i1 in the blood of AD patients and healthy controls, regardless of FLG null mutation status, serum IgE level and EASI score ( Figure 3A) . We found similar results in the skin ( Figure 3B and data not shown). Thus, in AD, the stability of FOXP3 expression in circulating Tregs is not altered.
| Production of IL-10 by ICOS + Tregs is impaired by cell death in AD
Effector/memory Tregs express high levels of ICOS, which contributes to the survival and expansion of Tregs. 36 Moreover, ICOS + Tregs, which likely derive from expansion of thymus-derived Tregs, are potentially highly suppressive. 37 We found that the percentages of ICOS + Tregs are increased in the blood of AD patients, regardless
of FLG mutation status, serum IgE level and EASI score ( Figure 4A ).
All Treg populations produce IL-10, whose proper secretion is necessary for immunosuppression. 38 However, ICOS + Tregs produce higher amounts of IL-10 compared to ICOS -Tregs and other T cells. 37 Moreover, ICOS is believed to be part of a switch mechanism for the production of IL-10. 39 To measure IL-10 production by Tregs, Figure 3A ).
| FLG null mutations amplify immune imbalance in Treg populations in AD patients
It is well-established that Tregs are as plastic as T cells. They can be skewed towards Th1-, Th2-or Th17-like cells via up-regulation of T-F I G U R E 3 Proportions of cells with demethylated FOXP3i1 are not altered in the blood of patients with AD. Proportions of cells with demethylated FOXP3i1 (A) in the blood or (B) in the skin of healthy controls and AD patients. Data were analysed using a Student′s t test or one-way ANOVA followed by a Tukey post-hoc test. Healthy controls are designated as CTRL (blood, n = 10; skin, n = 15); AD patients as AD (blood, n = 13; skin, n = 11), including patients without a FLG null mutation as AD WT/WT (blood, n = 7; skin, n = 7) and patients with a FLG null mutation as AD FLG MUT (blood, n = 6; skin, n = 4). AD patients were also stratified according to serum IgE level (<100 kU/l, blood, n = 4; >100 kU/l, blood, n = 9) or EASI score (<5, blood, n = 9; >5, blood, n = 4) . Data were analysed using a Student′s t test or one-way ANOVA followed by a Tukey post-hoc test with *P < 0.05, **P < 0.01, ***P < 0.0001. Healthy controls are designated as CTRL (n = 9); AD patients as AD (n = 9), including patients without a FLG null mutation as AD WT/WT (n = 5) and patients with a FLG null mutation as AD FLG MUT (n = 4). AD patients were also stratified according to serum IgE level (<100 kU/l, n = 3; >100 kU/l, n = 6) or EASI score (<5, n = 6; >5, n = 3) bet, GATA3 or RORγ respectively. 12, 21, 40 42 Thus, using the same strategy, we assessed the proportions of Th1-, Th2-and Th17-like Tregs in the blood of all participants. We first showed that Th1-, Th2-and Th17-like cells are present in the blood of healthy donors, with a predominance of Th2-like cells ( Figure S6 ). We found that the proportions of Th2-like Tregs were significantly increased in the blood of AD patients when compared to healthy controls, regardless of FLG mutation status, serum IgE level and EASI score, whereas the proportions of Th1-like Tregs were significantly reduced ( Figure 5A -B and Figure S6 ). In the case of Th17-like Tregs, they showed a tendency to be elevated in AD, especially in patients with a FLG null mutation ( Figure 5C ). Furthermore, ratios show a Th2/Th1 and Th17/ Th1 immune imbalance in AD patients, especially in those with a FLG null mutation ( Figure 5D ). There is no Th2/Th17 imbalance in AD patients when compared to healthy donors (data not shown).
Thus, in AD patients, circulating Tregs might be identically skewed towards a predominant Th2/Th17 immunity as observed in Th cell populations, thereby potentially amplifying immune abnormalities, especially in patients with FLG null mutations.
| DISCUSSION
AD is one of the most common skin diseases worldwide, with high comorbidity in its more severe forms. Indeed, AD can be accompanied by psychosocial problems, sleep deprivation, anorexia, depression and even suicidal ideation. 39 Unfortunately for the afflicted, there is no cure for AD and current therapeutic approaches are symptomatic despite extensive research. 9 Thus, identification of new potential therapeutic targets remains of interest for AD patients. The discovery of the key role of Tregs in cancer has spurred the development of new therapies based on checkpoint blockade. 23 However, in AD, a definitive role of Tregs remains to be demonstrated, thus, precluding Treg therapeutic targeting. Nonetheless, a consensus is emerging in support of elevated circulating Tregs in AD. 15-17,33,43-,45 Moreover, up-regulation of activation markers on circulating Tregs in adult AD is also well documented. 22 In contrast, in paediatric AD, there are fewer studies and the findings are more controversial. 46, 47 Contradictory results may be explained, in part, by the effects different treatments (eg, cyclosporine, glucocorticoids, UV irradiation) have on Tregs. 17 Thus, in this study, to circumvent age-and treatment-related bias, we recruited exclusively adult patients with no history of AD therapy.
We found the levels of circulating Tregs to be increased in these patients, potentially due to expansion of memory Tregs, especially the ICOS + fraction, but that FLG null mutations limit this expansion. impeding their production of IL-10 and, in turn, the efficacy of their immunosuppression.
In conclusion, we showed that in AD patients, FLG null mutations 
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F I G U R E 5 FLG null mutations amplify immune imbalance in Treg populations in patients with AD. Freshly collected blood cells were analysed by flow cytometry. Live lymphocytes were gated on CD4. Tregs were designated as CD4 + CD25 + CD127 low/-cells as depicted in Figure S1 . . Data were analysed using a Student′s t test or one-way ANOVA followed by a Tukey post-hoc test with *P < 0.05, **P < 0.01. Healthy controls are designated as CTRL (n = 8); AD patients as AD (n = 11), including patients without a FLG null mutation as AD WT/WT (n = 5) and patients with a FLG null mutation as AD FLG MUT (n = 6). AD patients were also stratified according to serum IgE level (<100 kU/l, n = 4; >100 kU/l, n = 7) or EASI score (<5, n = 7; >5, n = 4)
